Effect of Vinyl Polymers on Controlled Release Transdermal Patches of Ezetimibe

Background: The main objective of the study is to create and evaluate the effectiveness of transdermal patches containing ezetimibe. Ezetimibe is a pharmacological drug used to treat individuals diagnosed with hyperlipidaemia, a condition characterized by abnormal levels of lipids in the blood. It received FDA approval in 2002. Ezetimibe is the predominant nonstatin drug utilized to reduce LDL-C levels by approximately 13% to 20%. Ezetimibe functions as a suppressor of the process by which cholesterol is absorbed in the intestines. Method: The preparation of ezetimibe transdermal patches involved the use of polyvinyl pyrrolidone (PVP) and Poly vinyl alcohol (PVA) as polymers, PEG 4000 and propylene glycol as plasticizers and permeation enhancers. The patches were made utilizing the solvent casting method. Results:The prepared patches were assessed for their folding endurance values, which ranged from 90 to 100. This suggests that the created patches exhibit favorable flexibility and elasticity. The Ezetimibe patches formulated with polyvinyl pyrrolidone exhibited enhanced mechanical and tensile strength in comparison to the patches formulated with poly vinyl alcohol (PVA). The drug release trials demonstrated that the optimized formulation E-4 achieved a medication release rate of 93% after 12 hours. FTIR and DSC analyses were performed on the pure drug, polymers, and the optimized formulation E-4. The findings showed that no interaction was detected between the drug and the polymers Conclusion: Ezetimibe transdermal patches were made via solvent casting, effectively reducing lipid levels by inhibiting cholesterol and phytosterol absorption in the intestines.